Drug intelligence / Profile preview

hyoscine butylbromide + paracetamol + dicyclomine

Development stage
Unknown
Modality
Small Molecules
Administration
Oral
01

Overview

This drug is a fixed-dose combination of three active pharmaceutical ingredients—hyoscine butylbromide, paracetamol, and dicyclomine. It is formulated to provide comprehensive relief from abdominal pain, cramps, and spasms associated with gastrointestinal disorders such as irritable bowel syndrome (IBS), dysmenorrhea (menstrual cramps), renal colic, biliary colic, and other conditions involving smooth muscle spasm. - **Hyoscine butylbromide** acts as an antispasmodic by blocking muscarinic acetylcholine receptors in the smooth muscle of the gastrointestinal tract, thereby reducing spasms and discomfort. - **Dicyclomine** is also an anticholinergic/antispasmodic that relaxes intestinal smooth muscle through antagonism at muscarinic receptors (M1, M2, M3) and non-competitive inhibition of bradykinin and histamine effects on smooth muscle[6][7]. - **Paracetamol** functions as a non-opioid analgesic and antipyretic by inhibiting prostaglandin synthesis in the central nervous system to reduce pain perception and fever[4][5]. The combination targets both the underlying cause of spasms (via dual antispasmodics) and provides symptomatic relief from pain or fever (via paracetamol). This triple therapy may be used when single or dual combinations are insufficient for symptom control.

02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)M1 (Muscarinic acetylcholine receptor M1)CHRM3 (M3)CHRM2 (M2)

Beyond the preview

Go deeper on hyoscine butylbromide + paracetamol + dicyclomine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on hyoscine butylbromide + paracetamol + dicyclomine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call